Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Kraig Biocraft Laboratories (KBLB) Free Cash Flow (2016 - 2022)

Kraig Biocraft Laboratories (KBLB) has disclosed Free Cash Flow for 11 consecutive years, with -$441594.0 as the latest value for Q4 2022.

  • Quarterly Free Cash Flow fell 7.08% to -$441594.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$1.9 million through Dec 2022, up 0.57% year-over-year, with the annual reading at -$1.8 million for FY2025, 2.66% up from the prior year.
  • Free Cash Flow hit -$441594.0 in Q4 2022 for Kraig Biocraft Laboratories, up from -$485456.0 in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$32096.0 in Q3 2018 to a low of -$553272.0 in Q2 2021.
  • Historically, Free Cash Flow has averaged -$327434.5 across 4 years, with a median of -$418653.0 in 2021.
  • Biggest five-year swings in Free Cash Flow: surged 80.29% in 2018 and later tumbled 165.93% in 2019.
  • Year by year, Free Cash Flow stood at -$65642.0 in 2018, then crashed by 242.84% to -$225046.0 in 2019, then plummeted by 83.24% to -$412383.0 in 2021, then decreased by 7.08% to -$441594.0 in 2022.
  • Business Quant data shows Free Cash Flow for KBLB at -$441594.0 in Q4 2022, -$485456.0 in Q3 2022, and -$480818.0 in Q2 2022.